CSL says its CSL112 did not meet the primary efficacy endpoint in the Phase 3 AEGIS-II trial evaluating the highly-anticipated cholesterol efflux enhancer in reducing the risk of major adverse cardiovascular events.
Disappointment as CSL's leading heart candidate misses in clinical trial
February 13, 2024 Latest NewsBioPharmaNews of the Day![](https://e76bb9fd1f54a7a912eb-40f6ec802f763655ee14c32dfe77820e.ssl.cf4.rackcdn.com/c0bf415e5b95986a49039f549fe5af1f.jpg)
Latest Video
New Stories
-
The 'Week in Review' Podcast - 26 July
July 26, 2024 - - Podcast -
'We approached stakeholders that were highly engaged with the HTA review process'
July 26, 2024 - - Latest News -
Preaching transparency and not practising it is the worst possible look
July 26, 2024 - - Latest News -
Cartherics announces new licensing agreement for innovative cardiac cell therapy
July 25, 2024 - - Latest News -
New large study shows vaccination halves the risk of patients suffering Long-COVID
July 25, 2024 - - Latest News -
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 - - Latest News -
Telix completes significant raise that could be used for acquisitions
July 25, 2024 - - Latest News